Phase 3 RCT in 200 patients with newly diagnosed chronic phase CML: adding pegylated interferon alfa-2a to nilotinib raised MR4.5 at month 12 vs nilotinib alone (24% vs 15%, p=0.048), with additional side effects; grade 3-4 psychiatric events 6% vs 5%.
RCTn = 200
Nicolini et al. Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial